阿片类物质使用障碍的药物治疗：医师指南
Medications for Opioid Use Disorder: A Guide for Physicians.
作者信息
Azhar Naazia, Chockalingam Ravikumar, Azhar Asad
机构信息
Naazia Azhar, MD, MBA, is Instructor of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, and St. Louis Veterans Affairs Medical Center, St. Louis, Missouri. Ravikumar Chockalingam, MD, MPH, is at St. Louis Veterans Affairs Medical Center, St. Louis, Missouri. Asad Azhar, MD, Windsor University School of Medicine, Cayon, St. Kitts and Nevis.
出版信息
Mo Med. 2020 Jan-Feb;117(1):59-64.
Abstract
The opioid crisis has shaped the national public health dialogue for some time now. A "call to action" is a strong and resounding cry from multiple disciplines. This piece intends to detail the nuts and bolts of prescribing medications used for the treatment of opioid use disorder. The underlying message here is that opioid use disorder is a chronic, treatable illness and physicians of all specialties have a responsibility to not turn a blind eye.
摘要
一段时间以来，阿片类药物危机主导着全国公共卫生领域的讨论。“行动呼吁”是来自多个学科的强烈而响亮的呼声。本文旨在详细介绍用于治疗阿片类药物使用障碍的处方药物的具体细节。这里的潜在信息是，阿片类药物使用障碍是一种慢性、可治疗的疾病，所有专科的医生都有责任对此不视而不见。
相似文献
1
Medications for Opioid Use Disorder: A Guide for Physicians.
Mo Med. 2020 Jan-Feb;117(1):59-64.
2
Opioid Use Disorder: Medical Treatment Options.
Am Fam Physician. 2019 Oct 1;100(7):416-425.
3
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
CNS Drugs. 2020 Jun;34(6):629-642. doi: 10.1007/s40263-020-00719-3.
4
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
J Clin Psychopharmacol. 2016 Feb;36(1):100-3. doi: 10.1097/JCP.0000000000000448.
5
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
Drug Alcohol Depend. 2019 Jul 1;200:34-39. doi: 10.1016/j.drugalcdep.2019.02.031. Epub 2019 May 3.
6
Buprenorphine implants in medical treatment of opioid addiction.
Expert Rev Clin Pharmacol. 2017 Aug;10(8):799-807. doi: 10.1080/17512433.2017.1336434. Epub 2017 Jun 21.
7
Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
Adolesc Med State Art Rev. 2014 Aug;25(2):251-65.
8
Medications for management of opioid use disorder.
Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105.
9
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.
World J Biol Psychiatry. 2011 Apr;12(3):160-87. doi: 10.3109/15622975.2011.561872.
10
Adjunctive memantine for opioid use disorder treatment: A systematic review.
J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003. Epub 2019 Oct 20.
引用本文的文献
1
The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder.
Drug Alcohol Depend Rep. 2024 Apr 24;11:100235. doi: 10.1016/j.dadr.2024.100235. eCollection 2024 Jun.
2
Sulfonate-isosteric replacement examined within heroin-hapten vaccine design.
Bioorg Med Chem Lett. 2020 Sep 1;30(17):127388. doi: 10.1016/j.bmcl.2020.127388. Epub 2020 Jul 4.
3
Enhancement of a Heroin Vaccine through Hapten Deuteration.
J Am Chem Soc. 2020 Aug 5;142(31):13294-13298. doi: 10.1021/jacs.0c05219. Epub 2020 Jul 27.
本文引用的文献
1
Opioid Use Disorder Assessment Tools and Drug Screening.
Mo Med. 2019 Jul-Aug;116(4):318-324.
2
The importance of buprenorphine research in the opioid crisis.
Mol Psychiatry. 2019 May;24(5):626-632. doi: 10.1038/s41380-018-0329-5. Epub 2019 Jan 7.
3
The Opioid Crisis in Missouri: A Call to Action for Physicians, Legislators, and Society.
Mo Med. 2017 Nov-Dec;114(6):440-446.
4
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14.
5
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205. doi: 10.1001/jamapsychiatry.2017.3206.
6
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550.
7
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.
8
Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Addiction. 2016 Apr;111(4):695-705. doi: 10.1111/add.13238. Epub 2016 Jan 13.
9
Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.
Lancet Psychiatry. 2015 Oct;2(10):901-8. doi: 10.1016/S2215-0366(15)00366-1. Epub 2015 Sep 15.
10
Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.
Zotero 插件